Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 14, 2026HemaSphereOpen Access

Outcomes of therapy‐related non‐core binding factor acute myeloid leukemia with venetoclax‐based therapies

View Full Paper
Ask AI
Bookmark
Share

Authors

BCBing Z. CarterJCJennifer CrodenGGGuillermo Garcia‐Manero

Discussion

Loading...

Member takes

Overview

Observational study analyzes improved outcomes of venetoclax-based therapy in therapy-related acute myeloid leukemia, suggesting effective treatment strategies.

Key Points

  • This research aims to evaluate the effectiveness of venetoclax-based therapies in patients with therapy-related acute myeloid leukemia (T-AML).
  • Retrospective analysis of 317 adult patients with newly diagnosed T-AML.
  • Focused on patients receiving lower intensity therapy (LIT) regimens containing venetoclax.
  • Excluded patients with previous myeloid disorders; analyzed genetic mutations and karyotypes.
  • Complete response rates were higher with LIT + venetoclax than LIT alone (58% vs. 40%).
  • Patients receiving venetoclax had higher rates of allogeneic hematopoietic stem cell transplantation (22% vs. 7% for LIT).
  • Median overall survival was 8.4 months across the cohort; higher in patients with favorable risk genetics.

Cite This Study

Carter et al. (2026) studied this question.

synapsesocial.com/papers/699010f22ccff479cfe57371https://doi.org/10.1002/hem3.70317
View Full Paper
Ask AI
Bookmark
Share